39
Participants
Start Date
September 21, 2017
Primary Completion Date
December 27, 2022
Study Completion Date
January 16, 2023
Nab-paclitaxel 150 mg/m^2
Stage I (N=12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
Oxaliplatin 85 mg/m^2
Stage I (N= 12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
5-FU 1200 mg/m^2 x 2 D
Stage I (N= 12), on day 1 and day 15-16 Stage II (N= 25),on day 1 and day 15-16
Leucovorin 400 mg/m^2
Stage I (N= 12),on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
Michigan State University, Lansing
University of Iowa Hospitals and Clinics, Iowa City
University of Wisconsin, Madison
University of Minnesota, Minneapolis
Northwestern Medicine Lake Forest Hospital, Lake Forest
Northwestern University Feinberg School of Medicine, Chicago
Univeristy of Illinois Cancer Center, Chicago
Rutgers Cancer Institute of New Jersey, New Brunswick
Collaborators (1)
Celgene Corporation
INDUSTRY
Big Ten Cancer Research Consortium
OTHER
Al B. Benson, III, MD
OTHER